Evidence map›Paper›PMID 23334325›Full record

ArticleOncogene2014

Oncogenic K-Ras requires activation for enhanced activity.

H Huang, J Daniluk, Y Liu, J Chu, Z Li, B Ji, C D Logsdon

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncogene, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 97 papers.

0numbers the graph read from it
0cells of the map it votes in
97citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

97 citing papers in PubMed.

  1. Review
  2. Review
  3. Pancreatic cancer-associated myofibroblasts: a review.International journal of biological sciences · 2026
    Review
  4. Review
  5. Review
  6. Review
  7. Nuclear Galectin-1 promotesProceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. The Expressions of NF-κB, COX-2, Sp1, and c-Jun in Pancreatic Ductal Adenocarcinoma and Their Associations with Patient Survival.Pathophysiology : the official journal of the International Society for Pathophysiology · 2023
    Article
  19. Article
  20. Review

37 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

H Huang1] Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX, USA [2] Department of Gastroenterology, Changhai Hospital, Second Military Medical University, Shanghai, China.
J Daniluk1] Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX, USA [2] Department of Gastroenterology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland.
Y LiuDepartment of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
J ChuDepartment of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Z LiDepartment of Gastroenterology, Changhai Hospital, Second Military Medical University, Shanghai, China.
B JiDepartment of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, USA.
C D Logsdon1] Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX, USA [2] Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Tissue CoreP50CA102701 · NCI · MAYO CLINIC ROCHESTER · PI PETERSEN, GLORIA M. · 2004 to 2018
$32.7M
Paul Calabresi Program in Clinical/Translational Research at Mayo ClinicK12CA090628 · NCI · MAYO CLINIC ROCHESTER · PI WEROHA, SARAVUT · 2001 to 2025
$19.7M
SPORE in Pancreatic CancerP20CA101936 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ABBRUZZESE, JAMES L. · 2003 to 2009
$5.4M
MOLECULAR MECHANISMS OF PANCREATITISR01DK052067 · NIDDK · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LOGSDON, CRAIG D · 1998 to 2015
$4.4M
Develop and Characterize a Novel Animal Model of Pancreatic CancerR21CA155165 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI JI, BAOAN · 2011 to 2012
$379k
NCI NIH HHS CA016672NCI NIH HHS CA155165NCI NIH HHS K12 CA090628NCI NIH HHS P20 CA101936NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA102701NCI NIH HHS R21 CA155165NIDDK NIH HHS DK052067NIDDK NIH HHS R01 DK052067
6 · The paper itself

Abstract

Oncogenic Ras mutations are widely considered to be locked in a permanent 'On' state and 'constitutively active'. Yet, many healthy people have cells possessing mutant Ras without apparent harm, and in animal models mutant Ras causes transformation only after upregulation of Ras activity. Here, we demonstrate that oncogenic K-Ras is not constitutively active but can be readily activated by upstream stimulants to lead to prolonged strong Ras activity. These data indicate that in addition to targeting K-Ras downstream effectors, interventions to reduce K-Ras activation may have important cancer-preventive value, especially in patients with oncogenic Ras mutations. As other small G proteins are regulated in a similar manner, this concept is likely to apply broadly to the entire Ras family of molecules.

Indexed as

AnimalsBlotting, WesternCell Line, TumorCell Transformation, NeoplasticElectrophoresis, Polyacrylamide GelGenes, rasHumansMiceMice, Mutant StrainsMutationNeoplasmsProto-Oncogene Proteins p21(ras)Hras protein, mouseProto-Oncogene Proteins p21(ras)

Identifiers

PMID23334325
PMCPMC3923400

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.